产品
编 号：F080332
分子式：C23H19F6N3O
分子量：467.41
分子式：C23H19F6N3O
分子量：467.41
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 1221349-53-6
产品详情
生物活性：
TC-I 2014 (compound 5) is a potent and orally active Benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonist, with IC50 values of 0.8 nM, 3.0 nM and 4.4 nM for canine, human and rat channels respectively. TC-I 2014 exhibits antiallodynic properties in pain models.
体内研究：
TC-I 2014 (10 mg/kg, Orally once) completely prevents icilin-induced WDS.Animal Model:TC-I 2014 (10 mg/kg, Orally once) completely prevents icilin-induced WDS.
Dosage:3, 5.6, 10 mg/kg.
Administration:Orally once.
Result:Produced greater than 90% inhibition at 3, 5.6, and 10 mg/kg administered 2 h prior to icilin challenge.
体外研究：
TC-I 2014 (compound 5) potently inhibits cold-induced TRPM8 currents in HEK293 cells stably expressing canine or human TRPM8, with IC50 values of 0.413 and 1 nM, respectively.
TC-I 2014 (compound 5) is a potent and orally active Benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonist, with IC50 values of 0.8 nM, 3.0 nM and 4.4 nM for canine, human and rat channels respectively. TC-I 2014 exhibits antiallodynic properties in pain models.
体内研究：
TC-I 2014 (10 mg/kg, Orally once) completely prevents icilin-induced WDS.Animal Model:TC-I 2014 (10 mg/kg, Orally once) completely prevents icilin-induced WDS.
Dosage:3, 5.6, 10 mg/kg.
Administration:Orally once.
Result:Produced greater than 90% inhibition at 3, 5.6, and 10 mg/kg administered 2 h prior to icilin challenge.
体外研究：
TC-I 2014 (compound 5) potently inhibits cold-induced TRPM8 currents in HEK293 cells stably expressing canine or human TRPM8, with IC50 values of 0.413 and 1 nM, respectively.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备